StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $86.62 | $87.12 | +0.58% | 0.3M |
| 05-12 | $86.93 | $86.15 | -0.90% | 0.3M |
| 05-13 | $85.36 | $85.74 | +0.45% | 0.4M |
| 05-14 | $85.48 | $85.34 | -0.16% | 0.2M |
| 05-15 | $83.59 | $86.16 | +3.07% | 0.6M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $2.04M | $1.75M | $1.36M | $1.16M |
Operating Income | $-177.93M | $-108.39M | $-68.10M | $-33.18M |
Net Income | $-162.34M | $-97.91M | $-31.63M | $-29.51M |
EPS (Diluted) | $-4.20 | $-2.68 | $-1.71 | $-0.82 |
Total Assets | $530.92M | $577.45M | $326.08M | $348.58M |
Total Liabilities | $37.52M | $30.99M | $23.00M | $19.97M |
Cash & Equivalents | $51.09M | $55.98M | $13.24M | $10.12M |
Free Cash Flow OCF − CapEx | $-129.27M | $-82.15M | $-51.59M | $-27.65M |
Shares Outstanding | 43.22M | 42.85M | 32.18M | 32.13M |
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.